



EMvision Medical Devices Ltd
 ACN 620 388 230
 Level 10, 12 Creek Street,
 Brisbane Qld 4000
 02 8667 5337
 contact@emvision.com.au

ASX Release

RELEASE OF RESTRICTED SECURITIES FROM ESCROW

In connection with the official quotation of EMvision Medical Devices Limited's ("the Company") (ASX: EMV) fully paid ordinary shares on the ASX on 13th December 2018, certain security holders were required to enter into ASX imposed restriction agreements. These agreements restricted the relevant security holder from dealing in their securities for a range of periods set by the ASX, up to 24 months from the date of official quotation.

In accordance with Listing Rule 3.10A, the company advises that 1,793,250 fully paid ordinary shares in the Company are due to be released from escrow on 30th April 2019, being 12 months for the date of issue of these securities.

Application for quotation of 1,793,250 fully paid ordinary shares will be made following their release from restriction.

Thereafter, the following securities will remain subject to ASX restrictions with the restriction periods outlined below.

Class	Number	Restriction Period
Ordinary fully paid shares	16,789,351	24 months from the date of official quotation – 13 December 2020
Total Shares	16,789,351	
Options exercisable at \$0.35 each expiring on 31 Dec 2021	5,000,000	24 months from the date of official quotation – 13 December 2020
Options exercisable at \$0.35 each expiring on 31 Dec 2021	300,000	12 months from the date of issue of the securities – 17 July 2019
Total Options	5,300,000	
Performance Rights	6,000,000	24 months from the date of official quotation – 13 December 2020

In addition, the Company notes the following securities are subject to voluntary restrictions and the restriction periods applied to those securities is set out below.

Class	Number	Restriction Period
Ordinary fully paid shares	1,300,000	18 months from the date of official quotation – 13 June 2020
Options exercisable at \$0.35 each expiring on 31 Dec 2021	1,400,000	24 months from the date of official quotation – 13 December 2020

Capital Structure

There is no change to the capital structure of the Company, which is set out below, as a result of the release of securities from escrow.

Class	Number
Ordinary fully paid shares	57,578,750
Options exercisable at \$0.35 each expiring on 31 Dec 2021	7,500,000
Performance Rights	6,000,000

Emma Waldon
Company Secretary

[ENDS]

ABOUT EMVISION

EMvision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of over 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997.